These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26377590)

  • 1. Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
    Faivre SJ; Olszanski AJ; Weigang-Köhler K; Riess H; Cohen RB; Wang X; Myrand SP; Wickremsinhe ER; Horn CL; Ouyang H; Callies S; Benhadji KA; Raymond E
    Invest New Drugs; 2015 Dec; 33(6):1206-16. PubMed ID: 26377590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.
    Salazar R; Morales S; Gil-Martín M; Aguirre E; Oaknin A; Garcia M; Callies S; Wickremsinhe ER; Benhadji KA; Llombart A
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1205-15. PubMed ID: 24744161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.
    Yamamoto N; Nokihara H; Yamada Y; Uenaka K; Sekiguchi R; Makiuchi T; Slapak CA; Benhadji KA; Tamura T
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1645-55. PubMed ID: 23616084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
    Koolen SL; Witteveen PO; Jansen RS; Langenberg MH; Kronemeijer RH; Nol A; Garcia-Ribas I; Callies S; Benhadji KA; Slapak CA; Beijnen JH; Voest EE; Schellens JH
    Clin Cancer Res; 2011 Sep; 17(18):6071-82. PubMed ID: 21753156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.
    Infante JR; Benhadji KA; Dy GK; Fetterly G; Ma WW; Bendell J; Callies S; Adjei AA
    Invest New Drugs; 2015 Apr; 33(2):432-9. PubMed ID: 25640850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.
    Pratt SE; Durland-Busbice S; Shepard RL; Donoho GP; Starling JJ; Wickremsinhe ER; Perkins EJ; Dantzig AH
    Mol Cancer Ther; 2013 Apr; 12(4):481-90. PubMed ID: 23371859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
    Bhargava P; Marshall JL; Fried K; Williams M; Lefebvre P; Dahut W; Hanfelt J; Gehan E; Figuera M; Hawkins MJ; Rizvi NA
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):95-103. PubMed ID: 11561784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
    McKeage MJ; Jameson MB; Ramanathan RK; Rajendran J; Gu Y; Wilson WR; Melink TJ; Tchekmedyian NS
    BMC Cancer; 2012 Oct; 12():496. PubMed ID: 23098625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
    Infante JR; Weiss GJ; Jones S; Tibes R; Bauer TM; Bendell JC; Hinson JM; Von Hoff DD; Burris HA; Orlemans EO; Ramanathan RK
    Eur J Cancer; 2014 Nov; 50(17):2897-904. PubMed ID: 25262379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
    Michaelson MD; Zhu AX; Ryan DP; McDermott DF; Shapiro GI; Tye L; Chen I; Stephenson P; Patyna S; Ruiz-Garcia A; Schwarzberg AB
    Br J Cancer; 2013 Apr; 108(7):1393-401. PubMed ID: 23511559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
    Chow LQ; Eckhardt SG; O'Bryant CL; Schultz MK; Morrow M; Grolnic S; Basche M; Gore L
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):631-46. PubMed ID: 18058098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
    Richter S; Bedard PL; Chen EX; Clarke BA; Tran B; Hotte SJ; Stathis A; Hirte HW; Razak AR; Reedijk M; Chen Z; Cohen B; Zhang WJ; Wang L; Ivy SP; Moore MJ; Oza AM; Siu LL; McWhirter E
    Invest New Drugs; 2014 Apr; 32(2):243-9. PubMed ID: 23645447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
    Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
    Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
    Infante JR; Papadopoulos KP; Bendell JC; Patnaik A; Burris HA; Rasco D; Jones SF; Smith L; Cox DS; Durante M; Bellew KM; Park JJ; Le NT; Tolcher AW
    Eur J Cancer; 2013 Jun; 49(9):2077-85. PubMed ID: 23583440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors.
    Fountzilas C; Adjei A; Opyrchal M; Evans R; Ghasemi M; Attwood K; Groman A; Bshara W; Goey A; Wilton J; Ma WW; Iyer R
    Int J Cancer; 2021 Dec; 149(12):2063-2074. PubMed ID: 34319586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.
    Rixe O; Puzanov I; LoRusso PM; Cohen RB; Morris JC; Olowokure OO; Yin JY; Doroumian S; Shen L; Olszanski AJ
    Anticancer Drugs; 2015 Aug; 26(7):785-92. PubMed ID: 26020806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
    Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors.
    Malik L; Zwiebel A; Cooper J
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):533-539. PubMed ID: 30022224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
    Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
    Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.